Country for PR: United Kingdom
Contributor: PR Newswire Europe
Thursday, September 14 2017 - 00:31
Xultophy(R) Reduces Cardiovascular Risk Factors in People with Type 2 Diabetes
LISBON, Portugal, September 14, 2017 /PRNewswire-AsiaNet/ --

     Oral Presentation 113

    In people with type 2 diabetes, Xultophy(R) (insulin degludec/liraglutide) 
significantly reduced a number of risk factors associated with an increased 
risk of cardiovascular disease (CVD), compared to basal insulin.[1]

    According to a new post-hoc analysis presented today at the 53rd Annual 
Meeting of the European Association for the Study of Diabetes (EASD 2017), 
people treated with Xultophy(R)  had significantly lower systolic blood 
pressure, lower total cholesterol as well as lower low-density lipoprotein 
cholesterol (so-called 'bad cholesterol'), and significant weight changes in 
favour of Xultophy(R) compared to people treated with basal insulin (insulin 
glargine U100 or insulin degludec). A small but statistically significant 
increase in heart rate was also observed with Xultophy(R).[1]

    "People with type 2 diabetes have a higher risk of a heart attack or stroke 
compared to the general population, so reducing this risk as much as possible 
should be a central goal of treatment", said Professor Tina Vilsboll, Steno 
Diabetes Center Copenhagen, Denmark & Center for Diabetes Research, Gentofte 
Hospital, Copenhagen, Denmark. "I am very pleased to see the beneficial effects 
on cardiovascular risk markers provided by Xultophy (R)."

    CVD is the principal cause of death and disability among people with type 2 
diabetes globally, with approximately two-thirds of deaths in people with 
diabetes attributable to CVD.[2] Therefore, treatments for type 2 diabetes 
should not only lower blood sugar levels but also decrease CV risk.[3]

    "This added benefit of Xultophy(R) is certainly great news for the 
population at risk of developing cardiovascular disease on top of their 
existing type 2 diabetes", said Mads Krogsgaard Thomsen, executive vice 
president and chief science officer of Novo Nordisk. "At Novo Nordisk we strive 
to develop innovative treatments, reinforcing our long-term commitment to 
defeat diabetes. Xultophy(R) is a key component of this commitment."

    About the study

    The CV risk markers data came from a new post-hoc analysis of two 
Xultophy(R) randomised-controlled clinical trials, comparing the efficacy and 
safety of Xultophy(R) against insulin degludec in DUAL II and against insulin 
glargine U100 in DUAL V, both with metformin for 26 weeks.[4],[5] These trials 
were conducted in people with type 2 diabetes not achieving glycaemic control 
(HbA1c 7.5-10.0% in DUAL II; 7.0-10.0% in DUAL V) on basal insulin (20-40 units 
in DUAL II; 20-50 units in DUAL V). The primary results from these trials have 
been reported previously.[4],[5]

    About Xultophy(R)

    Xultophy(R) is a once-daily single injection fixed-ratio combination of 
long-acting insulin degludec (Tresiba(R)) and the GLP-1 receptor agonist 
liraglutide (Victoza(R)) in one pen. It is indicated for the treatment of 
adults with type 2 diabetes mellitus to improve glycaemic control in 
combination with oral glucose-lowering medicinal products when these alone or 
combined with basal insulin do not provide adequate glycaemic control. 
Xultophy(R) is given once daily by subcutaneous injection. Xultophy(R) can be 
administered at any time of the day with or without meals, preferably at the 
same time of the day.[6] On 18 September 2014, Xultophy(R) was granted 
marketing authorisation by the European Commission. On 21 November 2016, 
Xultophy(R) was approved by the FDA under the brand name Xultophy(R) 

    About Novo Nordisk

    Novo Nordisk is a global healthcare company with more than 90 years of 
innovation and leadership in diabetes care. This heritage has given us 
experience and capabilities that also enable us to help people defeat other 
serious chronic conditions: haemophilia, growth disorders and obesity. 
Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 
77 countries and markets its products in more than 165 countries. For more 
information, visit , Facebook 
[ ], Twitter 
[ ], LinkedIn 
[ ], YouTube 
[ ] .


    1. Vilsboll T BT, Bode BW, et al. IDegLira improves cardiovascular risk 
markers in patients with type 2 diabetes uncontrolled on basal insulin: 
analyses of DUAL II and DUAL V. Abstract at the 53rd Annual Meeting of the 
European Association for the Study of Diabetes (EASD), Lisbon, Portugal; 11-15 
September 2017.

    2. Low Wang C, Hess C, Goldfine A. Clinical update: cardiovascular disease 
in diabetes mellitus. Atherosclerotic cardiovascular disease and heart failure 
in type 2 diabetes mellitus - mechanisms, managment of patients with stable 
ischemic heart disease. J Am Coll Cardiol. 2016;60:e44-e164.

    3. Kurukulasuriya L, Sowers J. Therapies for type 2 diabetes: lowering 
HbA1c and associated cardiovascular risk factors. Cardiovasc Diabetol. 

    4. Buse JB, Vilsboll T, Thurman J, et al. Contribution of liraglutide in 
the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). 
Diabetes Care. 2014:2926-2933.

    5. Lingvay I, Harris S, Jaeckel E, et al. IDegLira was effective across a 
range of dysglycaemia and BMI categories in the DUAL V randomized trial. 
Diabetes Obes Metab. 2017. DOI: 10.1111/dom.13043.

    6. EMA. Xultophy(R) Summary of Product Characteristics. Available at: 
. Last accessed: September 2017.

    7. Novo Nordisk. Novo Nordisk recieves US FDA approval for Xultophy(R) 
100/3.6. Available at: Last 
accessed: September 2017.

    Further Information:

     Katrine Sperling            +45-4442-6718
     Asa Josefsson               +45-3079-7708
     Peter Hugreffe Ankersen     +45-3075-9085
     Hanna Ogren                 +45-3079-8519
     Anders Mikkelsen            +45-3079-4461
     Christina Jensen            +45-3079-3009
     Kasper Veje (US)            +1-609-235-8567

SOURCE:  Novo Nordisk